ClinicalTrials.gg
Not yet recruitingNCT07146204R-STAR-FIHUpdated Aug 28, 2025

First in Human Trial of R-Star: A Novel Robotic System for Minimally Invasive Coronary Artery Procedures.

An interventional study of Robotic-assisted percutaneous coronary intervention in Coronary Artery Disease, sponsored by Robocath. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Robocath · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies in Coronary Artery Disease with a site in France — 28 open to participants now, 44 under way, 6 of them phase 3. Coronary Artery Disease · France.

Planned enrollment
152nd of 158
20 · median 300
Started
2026
with 6 others
No phase
89 of 218
15 open now
Primary completion
2026-02
later than 11 of 43 live
Registered
210th of 218
by date

Among the 218 studies in Coronary Artery Disease with a site in France, this one is the 152nd largest by planned enrollment of the 158 interventional ones that give a count, is one of 7 that started in 2026, is one of 89 with no phase, reaches primary completion later than 11 of the 43 other live ones, and was the 210th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

28 of the 218 studies in Coronary Artery Disease with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Coronary Artery Disease with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the R-Star robotic system can be used safely and effectively to perform percutaneous coronary intervention (PCI) in adults with coronary artery disease who are scheduled for an elective PCI.

The main questions it aims to answer are:

  • Can PCI be completed with the robotic system without needing to switch fully to manual operation because of a technical issue or system limitation?
  • Is the treated artery adequately opened without complications during the procedure?

Participants will:

  • Have selection tests, including a medical exam, lab tests, ECG, and a review of their medical history.
  • Undergo PCI using the R-Star robotic system, with angiography before and after the procedure.
  • Have checkups before leaving the hospital and about 30 days later to monitor recovery and collect study data.
Read the detailed description

the R-STAR PCI FIH study is a prospective, interventional, first-in-human, exploratory, single-arm, open-label, pre-marketing pilot study conducted at a single site.

This study is designed to evaluate the safety and performance of the R-Two system, as well as the clinical feasibility of its use under normal conditions of use, in accordance with the General Safety and Performance Requirements pertaining to clinical evaluation of the device, as per Annex I of the Medical Device Regulation MDR 2017/745 (EU).

The study includes four visits. The baseline visit is performed prior to the index procedure and includes subject screening and eligibility verification as well as the informed consent process. The procedure visit (Day 0) corresponds to the index RA-PCI performed with the R-Two System and includes peri-procedural assessments. The post-procedure/hospital discharge visit (Day +1) allows for early follow-up and safety evaluation. Finally, the 30-day post-procedure visit (Day 30 ±7) is conducted to assess clinical status and collect follow-up information.

Based on preclinical findings and prior experience with robotic-assisted PCI, the R-Two platform is expected to demonstrate high levels of technical and clinical performance and safety in the intended population. The system is designed to reduce operator radiation exposure and to improve ergonomics by enabling remote operation from a control room, thereby limiting physical strain. Clinical outcomes are anticipated to be favorable, with low complication rates and improved operator working conditions. Secondary endpoints, such as procedure duration, fluoroscopy time, and contrast agent volume, are also expected to remain within clinically acceptable ranges.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • coronary artery disease
  • percutaneous coronary intervention
  • Robotic-assisted percutaneous coronary intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects eligible for inclusion in this study must meet all of the following inclusion criteria:
  • Patient ≥ 18 years old;
  • Patient with confirmed CAD, with indication for elective PCI;
  • Patient with CAD presenting the following specifications:

    • de novo native coronary artery lesion (i.e. a coronary lesion not previously treated)
    • Study reference vessel diameter is between 2.5 mm and 4.0 mm by visual estimate
    • Study lesion diameter showing stenosis of at least 50% by visual estimate.
  • Subject deemed appropriate for robotic-assisted PCI with R-Two system used per its intended use; based on the investigator's judgment;
  • The patient provides written as approved by the applicable Ethics Committee and is willing to comply with all study requirements including 30 day follow-up;
  • The patient is affiliated with a social security system.
  • Female subjects must be of non-child bearing potential, or if able to bear children, have a negative urinary pregnancy test within 7 days prior to the intended index procedure.

Exclusion criteria

Exclusion Criteria:

  • Planned PCI or coronary artery bypass graft (CABG) within 30 days after the study procedure.
  • Acute myocardial infarction within 72 hours before the study procedure.
  • \< 30%.
  • Recent PCI within 72 hours, or PCI within the past 30 days with a major adverse cardiac event.
  • Known allergy or to study-related medications or materials (aspirin, heparin, P2Y12 inhibitors, stainless steel, cobalt chromium, contrast media) not manageable with premedication.
  • Significant blood count abnormalities ( \< 100,000/mm³ or > 700,000/mm³; WBC \< 3,000/mm³).
  • Severe renal impairment (serum creatinine > 2.0 mg/dL or \< 30 mL/min).
  • Stroke within 30 days before the procedure.
  • Hemodynamic instability or acute pulmonary edema.
  • Significant active bleeding or high bleeding risk (recent GI bleeding, bleeding disorders, refusal of transfusion).
  • Pregnancy, breastfeeding, or planning pregnancy before study completion.
  • Current participation in another study without completed follow-up.
  • Angiographic exclusions: total occlusion, intraluminal thrombus, need for atherectomy or other non-balloon devices before stenting, unprotected left main stenosis > 50%, or certain bypass graft lesions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Study participants

    Patients with confirmed CAD, with indication for elective PCI

    Device: Robotic-assisted percutaneous coronary intervention

Interventions

  • DeviceRobotic-assisted percutaneous coronary intervention

    Patients with coronary artery disease will be treated usiing the R-Star robotic system for a robotic-assisted percutaneous coronary intervention

06

What researchers measure

Primary outcomes

  1. Technical success

    The technical success is defined as the rate of the robotic-assisted PCI completed without total manual conversion due to irretrievable technical issue or platform limitation leading to the inability of the devices to navigate vessel anatomy.

    Time frame: Periprocedural

Secondary outcomes

  1. Clinical success

    Less than 30% of residual stenosis post PCI in the lesions treated using the robotic system without target lesion failure (TLF) either within 48 hours of the procedure or prior to hospital discharge, whichever occurs first.

    Time frame: Within 48 hours of the procedure or prior to hospital discharge, whichever occurs first

  2. Absence of intra-procedural vascular complications

    Time frame: Periprocedural

  3. Absence of target lesion failure (TLF)

    Time frame: Hospital discharge visit 30-days follow up visit

  4. Absence of other device-related complications

    Time frame: Hopistal discharge visit 30-days follow-up visit

  5. Total and robotic procedure duration

    Time frame: Periprocedural

  6. Fluoroscpoy time

    Time frame: Periprocedural

  7. Radiation exposure for the patient and the primary operator

    Dose of radiation exposure for the patient and the primary operator

    Time frame: Periprocedural

  8. Score of operator ergonomic assessment scale

    This questionnaire is designed to assess your perceived ergonomic experience when using a robotic system compared to performing the same procedure manually. It covers several dimensions including physical, cognitive, organizational, environmental, and functional ergonomics.

    Time frame: Periprocedural

  9. Robotic precision as assessed by the rate of the longitudinal geographical miss

    The longitudinal geographical miss is determined by a core lab using a quantitative coronary angiography (QCA). Longitudinal geographic miss is defined as cases where the entire length of the injured or stenotic segment was not fully covered by the total length of the stent.

    Time frame: Procedure visit

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2026, 1 month later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 1 month is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 28, 2025
StartEst.
Jan 2026
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146204
Lead sponsor
Robocath
Collaborators
Veranex Switzerland SA
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jan 2026 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Hamouda Abassi, PhD
Contact
hamouda.abassi@robocath.com
+33 7 62 06 04 10

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion